On June 5, 2024, Percy Carter, Chief Scientific Officer of Blueprint Medicines Corp (NASDAQ:BPMC), sold 4,000 shares of the company.
On June 4, 2024, L. Hewes, Chief Medical Officer of Blueprint Medicines Corp (NASDAQ:BPMC), sold 2,424 shares of the company.
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced multiple upcoming datasets across two key conferences that reinforce the significant real-world burden of systemic mastocytosis (SM), and highlight the durable clinical outcomes of AYVAKIT®/AYVAKYT® (avapritinib) across the spectrum of the disease. The presentations, which build on over a decade of pioneering research with clinical experts and patient advocates, will be reported at the following meetings: